Outlook Therapeutics, Inc.
OTLK Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.4%, EPS grew 72.7%, free cash flow fell 76.5% and total debt fell 47.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OTLK
Outlook Therapeutics, Inc. (OTLK) EV/Sales
As of 16 October 2026, Outlook Therapeutics, Inc. (OTLK) trades at a EV/Sales of −73.2×. Over the past ten years it has ranged from −219× (July 2026) to 507× (June 2026); the current reading is higher than 3% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.1× | 171.77% |
| FY2019 | 3.7× | (78.68%) |
| FY2018 | 17.4× | 51.96% |
| FY2017 | 11.5× | (53.85%) |
| FY2016 | 24.8× | 35.67% |
| FY2015 | 18.3× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −202× | — |
| Mar 2026 | 109× | 361.35% |
| Dec 2025 | 23.7× | 134.88% |
| Sep 2025 | 10.1× | 2.26% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| OTLK Outlook Therapeutics, Inc. | −73.2× |
| VYGR Voyager Therapeutics, Inc. compare | 0.0× |
| NERV Minerva Neurosciences, Inc compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| SPRB Spruce Biosciences, Inc. compare | 1.5× |
| NRXP NRx Pharmaceuticals, Inc. compare | 22.6× |
| ABOS Acumen Pharmaceuticals, Inc. compare | 30.3× |
| HUMA Humacyte, Inc. compare | 40.3× |
| ARMP Armata Pharmaceuticals, Inc. compare | 68.8× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)